Welcome!

News Feed Item

MorphoSys and Lanthio Pharma Sign Technology Alliance on New Class of Therapeutic Peptides

MARTINSRIED, GERMANY and MUNICH, GERMANY -- (Marketwire) -- 11/27/12 -- MorphoSys AG / MorphoSys and Lanthio Pharma Sign Technology Alliance on New Class of Therapeutic Peptides. Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

MorphoSys to Participate in Lanthio Pharma's Series A Financing

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today announced a collaboration with privately held Lanthio Pharma, a Dutch biopharmaceutical company focused on discovering and developing lantipeptides. Lantipeptides comprise a novel class of therapeutics with high target selectivity and improved drug-like properties. Lanthio Pharma's technology LanthioPep can be used to identify peptides which are selective for a specific disease target and to stabilize them in their optimal structural conformation for receptor binding. MorphoSys and Lanthio Pharma will jointly apply their respective technologies to establish high quality and diverse lantipeptide-based libraries. MorphoSys receives preferred rights to exclusively license the LanthioPep technology for drug discovery.

MorphoSys will also make an equity investment in Lanthio Pharma as part of the company's Series A financing round. After closure of the transaction, MorphoSys will have a minority stake in Lanthio Pharma.

"Therapeutic peptides and especially so called stapled or constrained peptides comprise an emerging compound class which offers the potential to address multiple target classes and disease categories currently beyond reach for therapeutic proteins or small molecules. The combination of Lanthio Pharma's platform and our expertise in intelligent library design offers unique opportunities for both companies and that's what got us excited," commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG.

"We are very pleased to have access to this novel technology platform and promising class of therapeutic peptides," commented Jens Holstein, Chief Financial Officer of MorphoSys. "This transaction represents a new approach for MorphoSys providing innovation capital to promising start-ups with technologies and product candidates being close to our core capabilities."

Lanthio Pharma applies its proprietary LanthioPep technology to discover peptide therapeutics with increased resistance to peptidase degradation, high receptor specificity and increased intrinsic activity. The high specificity can open up new therapeutic applications around novel targets including intracellular targets and GPCRs. Therapeutic plasma levels of lantipeptides can potentially be achieved via oral, pulmonary or subcutaneous delivery. The technology includes a proprietary bacterial display capability, which allows for the construction of focused or diversified libraries of lanthionine-peptides. These libraries allow for immediate functional screening and easy production of peptides of interest for further in vivo and in vitro testing. Lanthio Pharma signed a partnering deal for its lead compound PanCyte, a lanthionine-stabilized Angiotensin-(1-7) agonistic peptide for the treatment of pulmonary indications, with US-based Tarix Pharmaceuticals, Inc. in 2012. The start of clinical development of PanCyte is expected in 2013.

"Peptides are an attractive class of drugs, because they are used by the body itself to regulate physiological processes. A drawback of using peptides therapeutically can be their ability to interact with several receptors and their rapid degradation by peptidases in the body. Lanthio Pharma's technology can make peptides more receptor specific and the introduction of lanthionines also provides strong protection against peptidase degradation. As such, our lantipeptides typically have better "drug-like" properties, compared to natural linear peptides. In combination with MorphoSys's outstanding capabilities in generating high-quality protein libraries we are confident that we can bring lantipeptides to the next level," commented Bart Wuurman, CEO of Lanthio Pharma.

About Lanthio Pharma:

Lanthio Pharma is a privately held drug discovery company that applies its proprietary Lactococcus lactis based lanthionine-peptide drug discovery (LanthioPep) technology to discover peptide therapeutics with increased resistance to peptidase degradation, high receptor specificity and increased intrinsic activity. Lanthio Pharma has generated stable, peptidase-resistant lanthionine peptides with highly specific agonistic activity for a number of GPCR targets, which is a focus area of the company. Many peptide ligands are thought to bind to their GPCR receptors via a "turn motif", which can be stabilized in Lanthio Pharma's peptides with a strong thioether bond. Fixing the turn motif in its optimal receptor binding conformation can result in potent and specific agonistic receptor activation. The technology also includes a proprietary bacterial display library capability, which allows for the construction of focused or randomized libraries. These libraries allow for immediate functional screening and easy production of peptides of interest for further in-vivo and in-vitro testing. Therapeutic products in Lanthio Pharma's pipeline include a lanthionine-stabilized specific agonist of the AT2 receptor, which has great potential in diseases where tissue protection is important, like fibrosis.

About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. The company's AbD Serotec unit uses HuCAL and other antibody technologies to generate superior monoclonal antibodies for research and diagnostic applications. Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 70 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla® and Ylanthia® and 100 billion high potentials® are registered trademarks of MorphoSys AG.

Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

Media Release (PDF): http://hugin.info/130295/R/1660628/537803.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE

[HUG#1660628]

For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Loser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Alexandra Goller
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

Email Contact

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
With billions of sensors deployed worldwide, the amount of machine-generated data will soon exceed what our networks can handle. But consumers and businesses will expect seamless experiences and real-time responsiveness. What does this mean for IoT devices and the infrastructure that supports them? More of the data will need to be handled at - or closer to - the devices themselves.
SYS-CON Events announced today that CollabNet, a global leader in enterprise software development, release automation and DevOps solutions, will be a Bronze Sponsor of SYS-CON's 20th International Cloud Expo®, taking place from June 6-8, 2017, at the Javits Center in New York City, NY. CollabNet offers a broad range of solutions with the mission of helping modern organizations deliver quality software at speed. The company’s latest innovation, the DevOps Lifecycle Manager (DLM), supports Value S...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In his Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will explore t...
Building a cross-cloud operational model can be a daunting task. Per-cloud silos are not the answer, but neither is a fully generic abstraction plane that strips out capabilities unique to a particular provider. In his session at 20th Cloud Expo, Chris Wolf, VP & Chief Technology Officer, Global Field & Industry at VMware, will discuss how successful organizations approach cloud operations and management, with insights into where operations should be centralized and when it’s best to decentraliz...
Multiple data types are pouring into IoT deployments. Data is coming in small packages as well as enormous files and data streams of many sizes. Widespread use of mobile devices adds to the total. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists will look at the tools and environments that are being put to use in IoT deployments, as well as the team skills a modern enterprise IT shop needs to keep things running, get a handle on all this data, and deli...
In his keynote at @ThingsExpo, Chris Matthieu, Director of IoT Engineering at Citrix and co-founder and CTO of Octoblu, focused on building an IoT platform and company. He provided a behind-the-scenes look at Octoblu’s platform, business, and pivots along the way (including the Citrix acquisition of Octoblu).
The Internet of Things is clearly many things: data collection and analytics, wearables, Smart Grids and Smart Cities, the Industrial Internet, and more. Cool platforms like Arduino, Raspberry Pi, Intel's Galileo and Edison, and a diverse world of sensors are making the IoT a great toy box for developers in all these areas. In this Power Panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists discussed what things are the most important, which will have the most profound e...
Automation is enabling enterprises to design, deploy, and manage more complex, hybrid cloud environments. Yet the people who manage these environments must be trained in and understanding these environments better than ever before. A new era of analytics and cognitive computing is adding intelligence, but also more complexity, to these cloud environments. How smart is your cloud? How smart should it be? In this power panel at 20th Cloud Expo, moderated by Conference Chair Roger Strukhoff, pane...
Grape Up is a software company, specialized in cloud native application development and professional services related to Cloud Foundry PaaS. With five expert teams that operate in various sectors of the market across the USA and Europe, we work with a variety of customers from emerging startups to Fortune 1000 companies.
SYS-CON Events announced today that Grape Up will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct. 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Grape Up is a software company specializing in cloud native application development and professional services related to Cloud Foundry PaaS. With five expert teams that operate in various sectors of the market across the U.S. and Europe, Grape Up works with a variety of customers from emergi...
Financial Technology has become a topic of intense interest throughout the cloud developer and enterprise IT communities. Accordingly, attendees at the upcoming 20th Cloud Expo at the Javits Center in New York, June 6-8, 2017, will find fresh new content in a new track called FinTech.
@ThingsExpo has been named the Most Influential ‘Smart Cities - IIoT' Account and @BigDataExpo has been named fourteenth by Right Relevance (RR), which provides curated information and intelligence on approximately 50,000 topics. In addition, Right Relevance provides an Insights offering that combines the above Topics and Influencers information with real time conversations to provide actionable intelligence with visualizations to enable decision making. The Insights service is applicable to eve...
SYS-CON Events announced today that Interoute, owner-operator of one of Europe's largest networks and a global cloud services platform, has been named “Bronze Sponsor” of SYS-CON's 20th Cloud Expo, which will take place on June 6-8, 2017 at the Javits Center in New York, New York. Interoute is the owner-operator of one of Europe's largest networks and a global cloud services platform which encompasses 12 data centers, 14 virtual data centers and 31 colocation centers, with connections to 195 add...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
20th Cloud Expo, taking place June 6-8, 2017, at the Javits Center in New York City, NY, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy.